A phase I, dose-escalation study to evaluate the safety and efficacy of MORAb-202 in patients with solid tumors that express folate receptor alpha (FRA).

Trial Profile

A phase I, dose-escalation study to evaluate the safety and efficacy of MORAb-202 in patients with solid tumors that express folate receptor alpha (FRA).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs MORAb-202 (Primary)
  • Indications Breast cancer; Endometrial cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2017 According to an Morphotek media release, first patient has been enrolled in the study.
    • 04 Dec 2017 Status changed from planning to recruiting, according to an Morphotek media release.
    • 25 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top